Compare Moderna, Inc. (MRNA) vs Wendys Co (WEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Wendys Co — how do they compare? Moderna, Inc. trades at $59.66 (market cap $23.60B), while Wendys Co trades at $7.63 (market cap $1.50B). The key difference: Moderna, Inc. is far larger — about 15.7× Wendys Co's market cap, and Wendys Co pays a 7.13% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | WEN | |
|---|---|---|
Market Cap | $23.60B | $1.50B |
Sector | Health | Consumer Cyclical |
52-Week High | $81.80 | $11.33 |
52-Week Low | $22.36 | $6.17 |
Enterprise Value | $19.70B | $5.31B |
Dividend Yield | — | 7.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $59.66, down 3.49% in the last session amid broader biotech volatility. The stock shows a mixed technical picture with bullish overall signals but bearish moving averages. Fundamentally, revenue has declined from pandemic peaks to $1.92B in 2025, with net losses widening to -$2.82B. Recent positive developments include an EU RSV vaccine contract and progress in cancer immunotherapy trials, with Q2 2026 earnings due July 31.
Outlook remains speculative as Moderna transitions beyond COVID-19 vaccines. Opportunities lie in its expanding pipeline in oncology and flu vaccines, but risks include sustained losses, competitive pressure, and execution hurdles. Analyst consensus is cautious with a $49 price target below current levels, reflecting uncertainty over profitability timeline.
Wendy's (WEN) trades at $7.63, down 1.68% on the day, with a bullish technical signal from moving averages and recent meme stock momentum. The company shows consistent earnings beats but faces margin pressure, with net income declining from $204M in 2023 to $165M in 2025. Valuation metrics appear attractive with a P/E of 10.2 and P/S of 0.69, while analyst consensus is mixed with a $7.96 price target.
The stock presents a value opportunity with solid dividends and low valuation, but investors face risks from declining profitability, high debt levels, and competitive pressures. Near-term catalysts include Q2 2026 earnings on August 7 and ongoing Project Fresh initiatives, though weak traffic and cost inflation remain headwinds for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Wendys Co
The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →
